We are analyzing https://link.springer.com/article/10.1186/1479-5876-8-56.

Title:
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies | Journal of Translational Medicine
Description:
Cutaneous melanoma is a very aggressive neoplasia of melanocytic origin with constantly growing incidence and mortality rates world-wide. Epigenetic modifications (i.e., alterations of genomic DNA methylation patterns, of post-translational modifications of histones, and of microRNA profiles) have been recently identified as playing an important role in melanoma development and progression by affecting key cellular pathways such as cell cycle regulation, cell signalling, differentiation, DNA repair, apoptosis, invasion and immune recognition. In this scenario, pharmacologic inhibition of DNA methyltransferases and/or of histone deacetylases were demonstrated to efficiently restore the expression of aberrantly-silenced genes, thus re-establishing pathway functions. In light of the pleiotropic activities of epigenetic drugs, their use alone or in combination therapies is being strongly suggested, and a particular clinical benefit might be expected from their synergistic activities with chemo-, radio-, and immuno-therapeutic approaches in melanoma patients. On this path, an important improvement would possibly derive from the development of new generation epigenetic drugs characterized by much reduced systemic toxicities, higher bioavailability, and more specific epigenetic effects.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

pubmed, google, scholar, cas, melanoma, methylation, dna, cancer, cells, epigenetic, expression, cell, histone, gene, res, genes, human, central, apoptosis, tumor, patients, malignant, promoter, drugs, clinical, modifications, aberrant, data, dnmt, mirna, table, activity, cpg, inhibitor, deacetylase, alterations, role, regulation, azacdr, treatment, hdaci, progression, specific, inhibitors, hypermethylation, clin, cutaneous, sigalotti, chromatin, line,

Topics {✒️}

malignant pleural mesothelioma sequential low-dose 5-aza-2'-deoxycytidine tnf-related apoptosis-inducing ligand low-dose 5-aza-2'-deoxycitidine treatment binding methyl-cpg-binding domain adoptive t-cell transfer mortality rates world-wide pro-angiogenic stimuli mediated skin malignancy-related deaths anti-5-methyl-cytosine antibodies full size image genome-wide integrative analysis induces mitochondria-dependent apoptosis article download pdf direct iap-binding protein involve histone hypoacetylation-mediated bisulfite-based methylation assays histone post-translational modifications hdaci-treated b16 cells methyl-cpg-binding proteins aberrant post-translational modifications serum er-α methylation high molecular weight-melanoma undergo immune-triggered apoptosis ssx cancer/testis antigens generation high-throughput technologies promoter methylation controls demethylating agent 5-aza-2'-deoxycytidine istituto di ricovero antigen-specific ctl response additional pre-clinical studies rna-induced silencing complex combined epigenetic chemo/radiotherapies open reading frame pro-apoptotic proteins apaf-1 central regulatory role dnmt inhibitor 5-aza-2'-deoxycytidine sodium butyrate-mediated apoptosis privacy choices/manage cookies antisense oligonucleotide mg98 alpha-aminosuberic acid histone deacetylase inhibitor p53-mediated pathway cancer/testis antigens expression sk-mel-28 melanoma cells tyrosinase-related protein 2 decitabine-mediated gene expression suberic bishydroxamic acid istituto toscano tumori prognostic epigenetic tools

Questions {❓}

Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, Pinto A, Gattei V, Maio M: 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies
         description:Cutaneous melanoma is a very aggressive neoplasia of melanocytic origin with constantly growing incidence and mortality rates world-wide. Epigenetic modifications (i.e., alterations of genomic DNA methylation patterns, of post-translational modifications of histones, and of microRNA profiles) have been recently identified as playing an important role in melanoma development and progression by affecting key cellular pathways such as cell cycle regulation, cell signalling, differentiation, DNA repair, apoptosis, invasion and immune recognition. In this scenario, pharmacologic inhibition of DNA methyltransferases and/or of histone deacetylases were demonstrated to efficiently restore the expression of aberrantly-silenced genes, thus re-establishing pathway functions. In light of the pleiotropic activities of epigenetic drugs, their use alone or in combination therapies is being strongly suggested, and a particular clinical benefit might be expected from their synergistic activities with chemo-, radio-, and immuno-therapeutic approaches in melanoma patients. On this path, an important improvement would possibly derive from the development of new generation epigenetic drugs characterized by much reduced systemic toxicities, higher bioavailability, and more specific epigenetic effects.
         datePublished:2010-06-11T00:00:00Z
         dateModified:2010-06-11T00:00:00Z
         pageStart:1
         pageEnd:22
         license:http://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1479-5876-8-56
         keywords:
            Cutaneous Melanoma
            Malignant Pleural Mesothelioma
            MGMT Promoter Methylation
            Cancer Testis Antigen
            Zebularine
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1479-5876-8-56/MediaObjects/12967_2010_Article_478_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1479-5876-8-56/MediaObjects/12967_2010_Article_478_Fig2_HTML.jpg
         isPartOf:
            name:Journal of Translational Medicine
            issn:
               1479-5876
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Luca Sigalotti
               affiliation:
                     name:Istituto di Ricovero e Cura a Carattere Scientifico
                     address:
                        name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Alessia Covre
               affiliation:
                     name:Istituto di Ricovero e Cura a Carattere Scientifico
                     address:
                        name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                        type:PostalAddress
                     type:Organization
                     name:University Hospital of Siena, Istituto Toscano Tumori
                     address:
                        name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elisabetta Fratta
               affiliation:
                     name:Istituto di Ricovero e Cura a Carattere Scientifico
                     address:
                        name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Giulia Parisi
               affiliation:
                     name:Istituto di Ricovero e Cura a Carattere Scientifico
                     address:
                        name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                        type:PostalAddress
                     type:Organization
                     name:University Hospital of Siena, Istituto Toscano Tumori
                     address:
                        name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Francesca Colizzi
               affiliation:
                     name:Istituto di Ricovero e Cura a Carattere Scientifico
                     address:
                        name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Aurora Rizzo
               affiliation:
                     name:Istituto di Ricovero e Cura a Carattere Scientifico
                     address:
                        name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Riccardo Danielli
               affiliation:
                     name:University Hospital of Siena, Istituto Toscano Tumori
                     address:
                        name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hugues JM Nicolay
               affiliation:
                     name:University Hospital of Siena, Istituto Toscano Tumori
                     address:
                        name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sandra Coral
               affiliation:
                     name:Istituto di Ricovero e Cura a Carattere Scientifico
                     address:
                        name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michele Maio
               affiliation:
                     name:Istituto di Ricovero e Cura a Carattere Scientifico
                     address:
                        name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                        type:PostalAddress
                     type:Organization
                     name:University Hospital of Siena, Istituto Toscano Tumori
                     address:
                        name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies
      description:Cutaneous melanoma is a very aggressive neoplasia of melanocytic origin with constantly growing incidence and mortality rates world-wide. Epigenetic modifications (i.e., alterations of genomic DNA methylation patterns, of post-translational modifications of histones, and of microRNA profiles) have been recently identified as playing an important role in melanoma development and progression by affecting key cellular pathways such as cell cycle regulation, cell signalling, differentiation, DNA repair, apoptosis, invasion and immune recognition. In this scenario, pharmacologic inhibition of DNA methyltransferases and/or of histone deacetylases were demonstrated to efficiently restore the expression of aberrantly-silenced genes, thus re-establishing pathway functions. In light of the pleiotropic activities of epigenetic drugs, their use alone or in combination therapies is being strongly suggested, and a particular clinical benefit might be expected from their synergistic activities with chemo-, radio-, and immuno-therapeutic approaches in melanoma patients. On this path, an important improvement would possibly derive from the development of new generation epigenetic drugs characterized by much reduced systemic toxicities, higher bioavailability, and more specific epigenetic effects.
      datePublished:2010-06-11T00:00:00Z
      dateModified:2010-06-11T00:00:00Z
      pageStart:1
      pageEnd:22
      license:http://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1479-5876-8-56
      keywords:
         Cutaneous Melanoma
         Malignant Pleural Mesothelioma
         MGMT Promoter Methylation
         Cancer Testis Antigen
         Zebularine
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1479-5876-8-56/MediaObjects/12967_2010_Article_478_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1479-5876-8-56/MediaObjects/12967_2010_Article_478_Fig2_HTML.jpg
      isPartOf:
         name:Journal of Translational Medicine
         issn:
            1479-5876
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Luca Sigalotti
            affiliation:
                  name:Istituto di Ricovero e Cura a Carattere Scientifico
                  address:
                     name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Alessia Covre
            affiliation:
                  name:Istituto di Ricovero e Cura a Carattere Scientifico
                  address:
                     name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                     type:PostalAddress
                  type:Organization
                  name:University Hospital of Siena, Istituto Toscano Tumori
                  address:
                     name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elisabetta Fratta
            affiliation:
                  name:Istituto di Ricovero e Cura a Carattere Scientifico
                  address:
                     name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Giulia Parisi
            affiliation:
                  name:Istituto di Ricovero e Cura a Carattere Scientifico
                  address:
                     name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                     type:PostalAddress
                  type:Organization
                  name:University Hospital of Siena, Istituto Toscano Tumori
                  address:
                     name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Francesca Colizzi
            affiliation:
                  name:Istituto di Ricovero e Cura a Carattere Scientifico
                  address:
                     name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Aurora Rizzo
            affiliation:
                  name:Istituto di Ricovero e Cura a Carattere Scientifico
                  address:
                     name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Riccardo Danielli
            affiliation:
                  name:University Hospital of Siena, Istituto Toscano Tumori
                  address:
                     name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hugues JM Nicolay
            affiliation:
                  name:University Hospital of Siena, Istituto Toscano Tumori
                  address:
                     name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sandra Coral
            affiliation:
                  name:Istituto di Ricovero e Cura a Carattere Scientifico
                  address:
                     name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michele Maio
            affiliation:
                  name:Istituto di Ricovero e Cura a Carattere Scientifico
                  address:
                     name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
                     type:PostalAddress
                  type:Organization
                  name:University Hospital of Siena, Istituto Toscano Tumori
                  address:
                     name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Translational Medicine
      issn:
         1479-5876
      volumeNumber:8
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Istituto di Ricovero e Cura a Carattere Scientifico
      address:
         name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
         type:PostalAddress
      name:Istituto di Ricovero e Cura a Carattere Scientifico
      address:
         name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
         type:PostalAddress
      name:University Hospital of Siena, Istituto Toscano Tumori
      address:
         name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
         type:PostalAddress
      name:Istituto di Ricovero e Cura a Carattere Scientifico
      address:
         name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
         type:PostalAddress
      name:Istituto di Ricovero e Cura a Carattere Scientifico
      address:
         name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
         type:PostalAddress
      name:University Hospital of Siena, Istituto Toscano Tumori
      address:
         name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
         type:PostalAddress
      name:Istituto di Ricovero e Cura a Carattere Scientifico
      address:
         name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
         type:PostalAddress
      name:Istituto di Ricovero e Cura a Carattere Scientifico
      address:
         name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
         type:PostalAddress
      name:University Hospital of Siena, Istituto Toscano Tumori
      address:
         name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
         type:PostalAddress
      name:University Hospital of Siena, Istituto Toscano Tumori
      address:
         name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
         type:PostalAddress
      name:Istituto di Ricovero e Cura a Carattere Scientifico
      address:
         name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
         type:PostalAddress
      name:Istituto di Ricovero e Cura a Carattere Scientifico
      address:
         name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
         type:PostalAddress
      name:University Hospital of Siena, Istituto Toscano Tumori
      address:
         name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Luca Sigalotti
      affiliation:
            name:Istituto di Ricovero e Cura a Carattere Scientifico
            address:
               name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Alessia Covre
      affiliation:
            name:Istituto di Ricovero e Cura a Carattere Scientifico
            address:
               name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
               type:PostalAddress
            type:Organization
            name:University Hospital of Siena, Istituto Toscano Tumori
            address:
               name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
               type:PostalAddress
            type:Organization
      name:Elisabetta Fratta
      affiliation:
            name:Istituto di Ricovero e Cura a Carattere Scientifico
            address:
               name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
               type:PostalAddress
            type:Organization
      name:Giulia Parisi
      affiliation:
            name:Istituto di Ricovero e Cura a Carattere Scientifico
            address:
               name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
               type:PostalAddress
            type:Organization
            name:University Hospital of Siena, Istituto Toscano Tumori
            address:
               name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
               type:PostalAddress
            type:Organization
      name:Francesca Colizzi
      affiliation:
            name:Istituto di Ricovero e Cura a Carattere Scientifico
            address:
               name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
               type:PostalAddress
            type:Organization
      name:Aurora Rizzo
      affiliation:
            name:Istituto di Ricovero e Cura a Carattere Scientifico
            address:
               name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
               type:PostalAddress
            type:Organization
      name:Riccardo Danielli
      affiliation:
            name:University Hospital of Siena, Istituto Toscano Tumori
            address:
               name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
               type:PostalAddress
            type:Organization
      name:Hugues JM Nicolay
      affiliation:
            name:University Hospital of Siena, Istituto Toscano Tumori
            address:
               name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
               type:PostalAddress
            type:Organization
      name:Sandra Coral
      affiliation:
            name:Istituto di Ricovero e Cura a Carattere Scientifico
            address:
               name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
               type:PostalAddress
            type:Organization
      name:Michele Maio
      affiliation:
            name:Istituto di Ricovero e Cura a Carattere Scientifico
            address:
               name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
               type:PostalAddress
            type:Organization
            name:University Hospital of Siena, Istituto Toscano Tumori
            address:
               name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
      name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
      name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
      name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
      name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
      name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
      name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
      name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
      name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
      name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
      name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
      name:Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
      name:Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy

External Links {🔗}(400)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

6.86s.

LINK . SPRINGER . COM {}